FDA sets Prescription Drug User Fee Act (PDUFA) date of March 10, 2027 Positions lonvo-z to be the world’s first in vivo CRISPR-based therapy an...
Agreement includes pre-payment commitments for product sales and distribution of the second-generation multi-cytokine-based HCW11-006 for use as a reagen...
GCCL (Global Clinical Central Lab), a South Korea-based leading provider of clinical trial sample analysis, announced its participation as a Platinum Spo...
Early detection remains one of the biggest challenges in cancer care, particularly for ovarian cancer, where symptoms can be difficult to r...
Thryv Therapeutics Inc. ("Thryv"), a clinical-stage biopharmaceutical company advancing selective SGK1 inhibitors, announced that it has entered into an ...
- Plozasiran reduced triglycerides (TG) by 79% and 81% versus placebo in SHASTA-3 and SHASTA-4 across the broad sHTG population - - More than 90% of p...
HUTCHMED (China) Limited announces positive high-level results from the SANOVO China Phase III trial in treatment-naïve patients with locally advanc...
The development of cannabinoid and psychedelic medicines is entering a more evidence-driven phase, with clinical validation, safety, regulatory a...
10x Genomics, Inc., the life science technology leader focused on accelerating science and advancing human health, announced that a jury in the U.S. Dist...
Announcing expansion of capabilities to provide customers with a broader range of DNA synthesis solutions, allowing IDT to complement and extend ...
New Curitics Point of Care Solution, Ambient Listening, AI Care Management, and mobile capabilities help reduce administrative burden, strengthen care co...
MaxCyte, Inc. (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development ...
Ecopipam (EBS-101) is a first-in-class selective D1 (dopamine) receptor antagonist with Orphan Drug designation NDA acceptance is supported by po...
Responding to a growing number of patients seeking personalized cancer immunotherapy, Immunocine Cancer Center has opened a second treatment location in ...
© 2026 Biopharma Boardroom. All Rights Reserved.
